Department of Neurology, Columbia University Medical Center, New York, NY 10032, USA.
J Inherit Metab Dis. 2011 Apr;34(2):261-76. doi: 10.1007/s10545-010-9082-x. Epub 2010 May 21.
This articles reviews the development of mitochondrial medicine from the premolecular era (1962-1988), when mitochondrial diseases were defined on the basis of clinical examination, muscle biopsy, and biochemical criteria, through the molecular era, when the full complexity of these disorders became evident. In a chronological order, I have followed the introduction of new pathogenic concepts that have shaped a rational genetic classification of these clinically heterogeneous disorders. Thus, mitochondrial DNA (mtDNA)-related diseases can be divided into two main groups: those that impair mitochondrial protein synthesis in toto, and those that affect specific respiratory chain proteins. Mutations in nuclear DNA can affect components of respiratory chain complexes (direct hits) or assembly proteins (indirect hits), but they can also impair mtDNA integrity (multiple mtDNA mutations), replication (mtDNA depletion), or mtDNA translation. Besides these disorders that affect the respiratory chain directly, defects in other mitochondrial functions may also affect oxidative phosphorylation, including problems in mitochondrial protein import, alterations of the inner mitochondrial membrane lipid composition, and defects of mitochondrial dynamics. The enormous and still ongoing progress in our understanding of mitochondrial medicine was made possible by the intense collaboration of an international cadre of "mitochondriacs." Having published my first paper on a patient with mitochondrial myopathy 37 years ago (DiMauro et al., 1973), I feel qualified to write a history of the mitochondrial diseases, a fascinating, still evolving, and continuously puzzling area of medicine. In each section, I follow a chronological order of the salient discoveries and I show only the portraits of distinguished deceased mitochondriacs and those whose names became eponyms of mitochondrial diseases.
这篇文章回顾了线粒体医学从前分子时代(1962-1988 年)的发展,当时线粒体疾病是根据临床检查、肌肉活检和生化标准来定义的,然后进入了分子时代,这些疾病的全部复杂性变得明显起来。按照时间顺序,我遵循了引入新的致病概念的顺序,这些概念为这些临床表现异质性疾病的合理遗传分类奠定了基础。因此,线粒体 DNA(mtDNA)相关疾病可以分为两大类:一类是完全损害线粒体蛋白合成的疾病,另一类是影响特定呼吸链蛋白的疾病。核 DNA 的突变可以影响呼吸链复合物的组成部分(直接作用)或组装蛋白(间接作用),但也可以损害 mtDNA 的完整性(多个 mtDNA 突变)、复制(mtDNA 耗竭)或 mtDNA 翻译。除了直接影响呼吸链的这些疾病外,其他线粒体功能的缺陷也可能影响氧化磷酸化,包括线粒体蛋白输入、线粒体内膜脂质组成的改变和线粒体动力学的缺陷。由于国际上一群“线粒体学家”的密切合作,我们对线粒体医学的理解取得了巨大的、仍在继续的进展。我在 37 年前发表了第一篇关于线粒体肌病患者的论文(DiMauro 等人,1973 年),因此我有资格撰写一部线粒体疾病的历史,这是一个引人入胜、仍在发展且不断令人困惑的医学领域。在每一节中,我都按照突出发现的时间顺序进行,我只展示杰出的已故线粒体学家和那些以他们的名字命名线粒体疾病的人的肖像。